ANGIOGENESIS IMAGING WITH CONTRAST-ENHANCED ULTRASOUND (CEUS) IN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES TREATED WITH BEVACIZUMAB - IRST 153.02

• Conditions: Patients affected by advanced colorectal carcinoma; MedDRA version: 9.1Level: SOCClassification code 10017947

• Registration Number: EUCTR2010-021248-16-IT
• Lead Sponsor: ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-12-22
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Written informed consent previously obtained in associated protocol • Enrolment in associated protocol; • Metastatic colorectal cancer with liver envolvment patients enrolled in associated trial; • Written informed consent for CEUS study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

• Contraindication to CEUS. SonoVue is controindicated in patients with recent acute coronary syndrome or clinical unstable ischaemic cardiac disease;in patients known to have right-to-left shunts,severe pulmonary hypertension (>90 mmhg),and in patients with adult respiratory distress syndrome; • Concomitant treatment with Cetuximab; • Previous surgical resection, termoablation, chemoembolization of liver metastases

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified